Recent News

• 08.28.2025 - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
• 08.19.2025 - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
• 07.21.2025 - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
• 06.25.2025 - Breakthroughs in CAR T-Cell Therapies Show Promise for Solid Tumor Cancers
• 06.12.2025 - Saving Time, Saving Lives: Natural Killer Cells and Cancer Therapy
• 05.27.2025 - Natural Killer Cells Are Revolutionizing Cancer Therapy

Recent Filings

• 08.28.2025 - EX-99.1 EX-99.1
• 08.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.19.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.21.2025 - EX-99.1 EX-99.1
• 07.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.23.2025 - 144 Report of proposed sale of securities